DOCSLIB.ORG

Franklin Biotechnology Discovery LU0109394709 31 August 2021 Fund - a (Acc) USD

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Franklin Biotechnology Discovery LU0109394709 31 August 2021 Fund - a (Acc) USD Franklin Templeton Investment Funds Sector Equity Franklin Biotechnology Discovery LU0109394709 31 August 2021 Fund - A (acc) USD Fund Fact Sheet For Professional Client Use Only. Not for distribution to Retail Clients. Fund Overview Performance Base Currency for Fund USD Performance over 5 Years in Share Class Currency (%) Total Net Assets (USD) 2.53 billion Franklin Biotechnology Discovery Fund A (acc) USD NASDAQ Biotechnology Index Fund Inception Date 03.04.2000 200 Number of Issuers 118 180 Benchmark NASDAQ Biotechnology Index 160 Morningstar Category™ Sector Equity Biotechnology 140 Summary of Investment Objective 120 The Fund aims to achieve capital appreciation by investing principally in equity securities of biotechnology companies 100 and discovery research firms mainly located in the US. Fund Management 80 08/16 02/17 08/17 02/18 08/18 02/19 08/19 02/20 08/20 02/21 08/21 Evan McCulloch, CFA: United States Discrete Annual Performance in Share Class Currency (%) Wendy Lam, PhD: United States 08/20 08/19 08/18 08/17 08/16 Akiva Felt: United States 08/21 08/20 08/19 08/18 08/17 A (acc) USD 7.90 34.74 -14.76 4.02 21.46 Ratings - A (acc) USD Benchmark in USD 25.46 31.77 -15.82 10.07 18.81 Overall Morningstar Rating™: Performance in Share Class Currency (%) Asset Allocation Cumulative Annualised Since Since 1 Mth 3 Mths 6 Mths YTD 1 Yr 3 Yrs 5 Yrs Incept 3 Yrs 5 Yrs Incept A (acc) USD 4.86 5.38 -6.17 -4.86 7.90 23.91 56.57 329.00 7.41 9.38 7.04 Benchmark in USD 4.09 12.19 8.32 12.37 25.46 39.16 82.00 401.99 11.64 12.73 7.83 Past performance is not an indicator or a guarantee of future performance. The value of shares in the Fund and income % received from it can go down as well as up, and investors may not get back the full amount invested. Performance details Equity 96.46 provided are in share class currency, include the reinvested dividends gross of basic rate UK tax and are net of management Cash & Cash Equivalents 3.54 fees. Sales charges and other commissions, other taxes and relevant costs to be paid by an investor are not included in the calculations. Performance may also be affected by currency fluctuations. Up to date performance figures can be found on our local website. When performance for either the portfolio or its benchmark has been converted, different foreign exchange closing rates may be used between the portfolio and its benchmark. Top Ten Holdings (% of Total) Fund Measures Issuer Name P/E to Growth 1.84x REGENERON PHARMACEUTICALS INC 5.82 Historical 3 Yr Sales Growth 46.70% AMGEN INC 4.72 Estimated 3-5 Yr EPS Growth 0.29% ILLUMINA INC 4.53 Price to Earnings (12-mo 16.16x GILEAD SCIENCES INC 4.50 Forward) HORIZON THERAPEUTICS PLC 3.81 Standard Deviation (5 Yrs) 22.00% MODERNA INC 3.62 Sharpe Ratio (5 Yrs) 0.38 BIOGEN INC 3.47 Tracking Error (5 Yrs) 7.09% NOVAVAX INC 3.04 Information Ratio (5 Yrs) -0.47 MIRATI THERAPEUTICS INC 2.98 Beta (5 Yrs) 1.02 VERTEX PHARMACEUTICALS INC 2.96 Share Class Information (For a full list of available share classes, please visit your local website) Fees Dividends Fund Identifiers Ongoing Max. Sales Max. Annual Last Paid Last Paid Share Class Incept Date NAV Charges (%) Charge (%) Charge (%) Frequency Date Amount SEDOL ISIN A (acc) USD 03.04.2000 USD 42.90 1.83 5.00 1.50 N/A N/A N/A 4161709 LU0109394709 UK Freefone Tel Fax E-Mail Web 0800 305 306 +44 20 7073 8690 +44 20 7073 8701 [email protected] www.franklintempleton.co.uk Franklin Biotechnology Discovery Fund 31 August 2021 For Professional Client Use Only. Not for distribution to Retail Clients. Composition of Fund Market Capitalisation Breakdown in USD % of Equity Performance Attribution by Country <2.0 Billion 21.35 01.09.2020-31.08.2021 Total Effect 2.0-5.0 Billion 15.53 United Kingdom 1.69 5.0-10.0 Billion 15.58 France 0.15 10.0-25.0 Billion 11.13 Israel 0.05 25.0-50.0 Billion 2.52 Belgium -0.02 >50.0 Billion 33.26 Spain -0.03 N/A 0.63 Sweden -0.04 Netherlands -0.08 Performance Attribution by Security Ireland -0.10 01.09.2020-31.08.2021 Total Effect Switzerland -0.16 5 Largest Contributing Securities Canada -0.26 IMMUNOMEDICS INC 2.41 China -0.28 GW PHARMACEUTICALS PLC 2.03 Denmark -0.40 NOVAVAX INC 0.87 Germany -1.67 FATE THERAPEUTICS INC 0.83 United States -13.00 *INCYTE CORP 0.81 Cash & Cash Equivalents -1.44 5 Smallest Contributing Securities GLOBAL BLOOD THERAPEUTICS INC -0.86 DECIPHERA PHARMACEUTICALS INC -0.98 IOVANCE BIOTHERAPEUTICS INC -1.08 BIONTECH SE -1.43 MODERNA INC -8.69 *Security not held in the portfolio at the end of the reporting period. Largest Contributing Securities 01.08.2021-31.08.2021 Contribution to Return % Regeneron Pharmaceuticals, Inc. Pharmaceuticals Biotechnology & Life Sciences United States 0.98 Novavax, Inc. Pharmaceuticals Biotechnology & Life Sciences United States 0.95 Trillium Therapeutics Inc. Pharmaceuticals Biotechnology & Life Sciences Canada 0.73 Ascendis Pharma A/S Sponsored ADR Pharmaceuticals Biotechnology & Life Sciences Denmark 0.66 PTC Therapeutics, Inc. Pharmaceuticals Biotechnology & Life Sciences United States 0.32 Gilead Sciences, Inc. Pharmaceuticals Biotechnology & Life Sciences United States 0.32 Horizon Therapeutics Public Limited Company Pharmaceuticals Biotechnology & Life Sciences United States 0.31 Seagen, Inc. Pharmaceuticals Biotechnology & Life Sciences United States 0.24 Sutro Biopharma, Inc. Pharmaceuticals Biotechnology & Life Sciences United States 0.24 Adagio Therapeutics, Inc. Pharmaceuticals Biotechnology & Life Sciences United States 0.23 Smallest Contributing Securities 01.08.2021-31.08.2021 Contribution to Return % Jazz Pharmaceuticals Public Limited Company Pharmaceuticals Biotechnology & Life Sciences United States -0.62 Illumina, Inc. Pharmaceuticals Biotechnology & Life Sciences United States -0.43 Amgen Inc. Pharmaceuticals Biotechnology & Life Sciences United States -0.34 Reata Pharmaceuticals, Inc. Class A Pharmaceuticals Biotechnology & Life Sciences United States -0.29 Fate Therapeutics, Inc. Pharmaceuticals Biotechnology & Life Sciences United States -0.21 Zogenix, Inc. Pharmaceuticals Biotechnology & Life Sciences United States -0.11 Heron Therapeutics Inc Pharmaceuticals Biotechnology & Life Sciences United States -0.10 Arcus Biosciences, Inc. Pharmaceuticals Biotechnology & Life Sciences United States -0.09 ACADIA Pharmaceuticals Inc. Pharmaceuticals Biotechnology & Life Sciences United States -0.09 Silverback Therapeutics, Inc. Pharmaceuticals Biotechnology & Life Sciences United States -0.07 What Are the Key Risks? The value of shares in the Fund and income received from it can go down as well as up and investors may not get back the full amount invested. Performance may also be affected by currency fluctuations. Currency fluctuations may affect the value of overseas investments. The Fund invests mainly in equity securities of biotechnology companies. Such securities have historically been subject to significant price movements that may occur suddenly due to market, sector or company-specific factors. As a result, the performance of the Fund can fluctuate very significantly over relatively short time periods. Other significant risks include: securities lending risk, equity risk. For full details of all of the risks applicable to this Fund, please refer to the “Risk Considerations” section of the Fund in the current prospectus of Franklin Templeton Investment Funds. Important Information This document is intended to be of general interest only and does not constitute legal or tax advice nor is it an offer for shares or invitation to apply for shares of the Franklin Templeton Investment Funds SICAV (the Fund). Nothing in this document should be construed as investment advice. Subscriptions to shares of the Fund can only be made on the basis of the current prospectus and where available, the relevant Key Investor Information Document, accompanied by the latest available audited annual report and the latest semi-annual report if published thereafter. No shares of the Fund may be directly or indirectly offered or sold to residents of the United States of America. Shares of the Fund are not available for distribution in all jurisdictions and prospective investors should confirm availability with their local Franklin Templeton representative before making any plans to invest. References to particular industries, sectors or companies are for general information and are not necessarily indicative of a Funds's holding at any one time. The value of shares in the Fund and income received from it can go down as well as up, and investors may not get back the full amount invested. All or most of the protections provided by the UK Regulatory System will not apply to Franklin Templeton Investment Funds (SICAV) Investors. An investment in the Fund entails risks which are described in the Fund's prospectus and where available, the relevant Key Investor Information Document. Source for data and information provided by Franklin Templeton, as of the date of this document, unless otherwise noted. Benchmark related data provided by FactSet, as of the date of this document, unless otherwise noted. References to indices are made for comparative purposes only and are provided to represent the investment environment existing during the time periods shown. An index is unmanaged and one cannot invest directly in an index. The performance of the index does not include the deduction of expenses and does not represent the performance of any Franklin Templeton fund. The Fund invests in a specific sector or geographical area and the returns may be more volatile than a more diversified fund. Fund Management: CFA® and Chartered Financial Analyst® are trademarks owned by CFA Institute.
Load more

Recommended publications
  • Prostate Cancer in Focus
    PROSTATE CANCER IN FOCUS Current Developments in the Management of Prostate Cancer Section Editor: Andrew J. Armstrong, MD Prostate Cancer Prostate PSMA-Targeted Therapy in Prostate Cancer Scott T. Tagawa, MD, MS Professor of Medicine and Urology Weill Cornell Medicine New York, New York H&O What is prostate-specific membrane agent such as a monoclonal antibody might be able to antigen (PSMA), and what makes it a good target target a tumor without binding to other PSMA-positive for the treatment of prostate cancer? sites owing to its large size and physical inability to reach luminal sites of expression that are separated from the ST PSMA is a cell surface antigen that is expressed to vasculature by tight junctions. a limited degree on certain normal cells in the body but generally is highly overexpressed in the setting of prostate H&O How is PSMA positivity established? cancer. Normal cells that express PSMA are located in the prostate, salivary, and lacrimal glands; the proximal part ST Imaging and biopsy are the main ways to establish of the small intestine; the proximal renal tubules; and PSMA positivity. Multiple imaging modalities are avail- some ganglia. In the setting of prostate cancer, PSMA able worldwide. The agent indium In 111 capromab expression generally increases along with the cancer grade, pendetide (ProstaScint) has been approved for years in and it also increases following hormonal therapy. In addi- the United States, and the US Food and Drug Adminis- tion, PSMA expression tends to be higher in metastatic tration (FDA) approved the use of gallium Ga 68 PSMA- sites than in primary tumors.
    [Show full text]
  • Refreshing the Biologic Pipeline 2020
    news feature Credit: Science Lab / Alamy Stock Photo Refreshing the biologic pipeline 2020 In the absence of face-to-face meetings, FDA and industry implemented regulatory workarounds to maintain drug and biologics approvals. These could be here to stay. John Hodgson OVID-19 might have been expected since 1996) — a small miracle in itself “COVID-19 confronted us with the need to severely impair drug approvals (Fig. 1 and Table 1). to better triage sponsors’ questions,” says Cin 2020. In the event, however, To the usual crop of rare disease and Peter Marks, the director of the Center for industry and regulators delivered a small genetic-niche cancer treatments, 2020 Biologics Evaluation and Research (CBER) miracle. They found workarounds and also added a chimeric antigen receptor at the FDA. “That was perhaps the single surrogate methods of engagement. Starting (CAR)-T cell therapy with a cleaner biggest takeaway from the pandemic related in January 2020, when the outbreak veered manufacturing process and the first to product applications.” Marks says that it westward, the number of face-to face approved blockbuster indication for a became very apparent with some COVID- meetings declined rapidly; by March, small-interfering RNA (siRNA) — the 19-related files that resolving a single they were replaced by Webex and Teams. European Medicines Agency’s (EMA) issue can help a sponsor enormously and (Secure Zoom meeting are to be added registration of the RNA interference accelerate the development cycle. Before this year.) And remarkably, by 31 December, (RNAi) therapy Leqvio (inclisiran) for COVID-19, it was conceivable that a small the US Food and Drug Administration cardiovascular disease.
    [Show full text]
  • VIRTUS ZEVENBERGEN INNOVATIVE GROWTH STOCK FUND SCHEDULE of INVESTMENTS (Unaudited) MARCH 31, 2021
    VIRTUS ZEVENBERGEN INNOVATIVE GROWTH STOCK FUND SCHEDULE OF INVESTMENTS (Unaudited) MARCH 31, 2021 ($ reported in thousands) Shares Value Shares Value Footnote Legend: (1) Non-income producing. COMMON STOCKS—99.0% Industrials—3.9% Communication Services—9.3% Desktop Metal, Inc. (1) Country Weightings† Coursera, Inc.(1) 7,100 $ 320 Class A 359,800 $ 5,361 (1) Uber Technologies, United States 87% Netflix, Inc. 84,500 44,080 (1) Snap, Inc. Class A(1) 586,650 30,676 Inc. 897,900 48,944 Canada 7 Zillow Group, Inc. 54,305 Brazil 5 Class C(1) 434,335 56,307 Israel 1 Information Technology—43.9% Total 100% 131,383 (1) Coupa Software, Inc. 78,450 19,964 † (1) % of total investments as of March 31, 2021. Consumer Discretionary—25.3% fuboTV, Inc. 315,350 6,976 (1) NVIDIA Corp. 107,000 57,131 Airbnb, Inc. Class A 91,100 17,121 (1) Amazon.com, Inc.(1) 15,200 47,030 Okta, Inc. 235,575 51,928 (1) Paylocity Holding Chegg, Inc. 322,325 27,610 (1) (1) Corp. 110,750 19,916 Chewy, Inc. Class A 340,400 28,835 (1) Fiverr International PayPal Holdings, Inc. 198,850 48,289 Ltd.(1) 27,650 6,005 QUALCOMM, Inc. 204,050 27,055 RingCentral, Inc. Lululemon Athletica, (1) (1) Class A 129,800 38,665 Inc. 41,690 12,787 (1) (1) ServiceNow, Inc. 78,325 39,171 MercadoLibre, Inc. 48,225 70,994 (1) Peloton Interactive, Inc. Shopify, Inc. Class A 78,200 86,528 (1) Snowflake, Inc. Class A 336,850 37,876 (1) Tesla, Inc.(1) 162,740 108,699 Class A 110,700 25,381 Sprout Social, Inc.
    [Show full text]
  • Doctor of Pharmacy Fellowship Program
    2021-2022 Doctor of Pharmacy Fellowship Program Accelerate your career with one of our 1-year fellowship programs Transformative Therapies Targeting Cancer Seagen Inc. is a global biotechnology company dedicated to discovering, developing, and commercializing transformative YEARS: In oncology for 23+ years cancer medicines to make a meaningful difference in people’s lives. SIZE: Largest biotechnology company ADCETRIS® (brentuximab vedotin) and PADCEV® (enfortumab vedotin-ejfv) use based in the Pacific Northwest the company’s industry-leading antibody-drug conjugate (ADC) technology. ADCETRIS is approved in certain CD30-expressing lymphomas, and PADCEV is EMPLOYEES: 2,200+ employees approved in certain metastatic urothelial cancers. TUKYSA® (tucatinib), a small mole- worldwide cule tyrosine kinase inhibitor, is approved in certain HER2-positive metastatic breast cancers. The company is headquartered in Seattle, Washington area, with loca- PASSION: Helping people with cancer tions in California, Switzerland and the European Union. Beyond our approved prod- ucts, the company has established a pipeline of novel targeted therapies at various stages of clinical testing. OUR MISSION OUR VALUES To discover, develop, and Passion for helping patients commercialize transformative cancer Revolutionizing therapies for people medicines to make a meaningful living with cancer difference in people’s lives. Integrity Honesty, respect and trust guide us Scientific excellence Premier science empowers our passion We have built a strong Diversity, teamwork, and corporate culture around our mutual respect mission and values. Seagen Shared dedication and diverse embodies an entrepreneurial perspectives drive successful spirit that advances collaborations breakthrough therapies, Innovation which is why we are the Entrepreneurial spirit advances leader in antibody-drug breakthrough therapies conjugate technology.
    [Show full text]
  • FTIF - Franklin Global Growth Fund August 31, 2021
    FTIF - Franklin Global Growth Fund August 31, 2021 FTIF - Franklin Global Growth August 31, 2021 Fund Portfolio Holdings The following portfolio data for the Franklin Templeton funds is made available to the public under our Portfolio Holdings Release Policy and is "as of" the date indicated. This portfolio data should not be relied upon as a complete listing of a fund's holdings (or of a fund's top holdings) as information on particular holdings may be withheld if it is in the fund's interest to do so. Additionally, foreign currency forwards are not included in the portfolio data. Instead, the net market value of all currency forward contracts is included in cash and other net assets of the fund. Further, portfolio holdings data of over-the-counter derivative investments such as Credit Default Swaps, Interest Rate Swaps or other Swap contracts list only the name of counterparty to the derivative contract, not the details of the derivative. Complete portfolio data can be found in the semi- and annual financial statements of the fund. Security Security Shares/ Market % of Coupon Maturity Identifier Name Positions Held Value TNA Rate Date G6095L109 APTIV PLC 70,000 $10,653,300 3.09% N/A N/A 045327103 ASPEN TECHNOLOGY INC 58,000 $7,511,000 2.18% N/A N/A BRIGHT HORIZONS FAMILY SOLUTIONS 109194100 49,000 $7,142,240 2.07% N/A N/A INC BROADRIDGE FINANCIAL SOLUTIONS 11133T103 46,000 $7,922,120 2.30% N/A N/A INC 124765108 CAE INC 360,000 $10,394,547 3.01% N/A N/A CHARLES RIVER LABORATORIES 159864107 27,000 $11,984,220 3.47% N/A N/A INTERNATIONAL
    [Show full text]
  • Franklin Templeton Investment Funds Franklin Biotechnology Discovery Fund a (Acc) USD This Fund Is Managed by Franklin Templeton International Services S.À R.L
    31 May, 2021 Franklin Templeton Investment Funds Franklin Biotechnology Discovery Fund A (acc) USD This fund is managed by Franklin Templeton International Services S.à r.l. EFC Classification Equity Biotechnology Price +/- Date 52wk range 40.80 EUR 0.13 28/05/2021 36.82 50.31 Issuer Profile Administrator Franklin Templeton International Services S.à r.l. The Fund aims to achieve capital appreciation by investing principally in equity securities Address 8A, rue Albert Borschette 1246 of biotechnology companies and discovery research firms mainly located in the US. City Luxembourg Tel/Fax +352 46 66 67 212 Chart 5 year Website www.franklintempleton.lu General Information ISIN LU0109394709 Fund Type Capitalization 50 Quote Frequency daily Quote Currency USD 45 Currency USD Foundation Date 03/04/2000 40 Fund Manager Wendy Lam Legal Type Investment company according to Luxembourg law 35 UCITS Yes Financial Year End 30/06/2020 30 Fund size 1,786,183,025.88 USD Minimal Order 5,000.00 USD 25 Costs 20 Entry fee 5.75 % 2017 2018 2019 2020 2021 Infront Finance Exit fee 0.00 % 38 Days 200 Days Operation costs 1.50 % Ongoing charges 1.83 % Fund Returns 2016 2017 2018 2019 2020 2021 Returns -15.18 2.77 -12.34 36.10 16.74 -8.55 Category Average Category Ranking / / / / / / 40 20 s e u l a V 0 -20 2016 2017 2018 2019 2020 2021 Returns Category Average Fund Ratios (end previous month) Timing YTD 1 month 6 months 1 year 3 year 5 year Performance Franklin Templeton Investment Funds Franklin Biotechnology Discovery Fund A (acc) USD -4.26 % 0.75 % 10.52 % 23.66 % 12.07 % 10.78 % Volatility Franklin Templeton Investment Funds Franklin Biotechnology Discovery Fund A (acc) USD 15.27 % 22.74 % 21.59 % 31 May, 2021 Franklin Templeton Investment Funds Franklin Biotechnology Discovery Fund A (acc) USD This fund is managed by Franklin Templeton International Services S.à r.l.
    [Show full text]
  • Franklin Templeton Investment Funds Franklin Biotechnology Discovery Fund a (Acc) USD This Fund Is Managed by Franklin Templeton International Services S.À R.L
    22 February, 2021 Franklin Templeton Investment Funds Franklin Biotechnology Discovery Fund A (acc) USD This fund is managed by Franklin Templeton International Services S.à r.l. EFC Classification Equity United States Health Care Price +/- Date 52wk range 48.62 EUR 0.68 19/02/2021 26.23 50.31 Issuer Profile Administrator Franklin Templeton International Services S.à r.l. The Fund aims to achieve capital appreciation by investing principally in equity securities Address 8A, rue Albert Borschette 1246 of biotechnology companies and discovery research firms mainly located in the US. City Luxembourg Tel/Fax +352 46 66 67 212 Chart 5 year Website www.franklintempleton.lu General Information ISIN LU0109394709 Fund Type Capitalization 50 Quote Frequency daily Quote Currency USD 45 Currency USD Foundation Date 03/04/2000 40 Fund Manager Wendy Lam Legal Type Investment company according to Luxembourg law 35 UCITS Yes Financial Year End 30/06/2020 30 Fund size 1,605,796,760.42 USD Minimal Order 5,000.00 USD 25 Costs 20 Entry fee 5.75 % 2017 2018 2019 2020 2021 Infront Finance Exit fee 0.00 % 38 Days 200 Days Operation costs 1.00 % Ongoing charges 1.83 % Fund Returns 2016 2017 2018 2019 2020 2021 Returns -15.18 2.77 -12.34 36.10 16.74 9.00 Category Average -7.83 7.56 1.62 26.74 12.02 4.75 Category Ranking 215 / 251 238 / 288 303 / 319 34 / 384 102 / 443 68 / 508 40 20 s e u l a V 0 -20 2016 2017 2018 2019 2020 2021 Returns Category Average Fund Ratios (end previous month) Timing YTD 1 month 6 months 1 year 3 year 5 year Performance Franklin Templeton Investment Funds Franklin Biotechnology Discovery Fund A (acc) USD 0.22 % 0.22 % 13.91 % 34.21 % 10.46 % 12.16 % Volatility Franklin Templeton Investment Funds Franklin Biotechnology Discovery Fund A (acc) USD 22.42 % 22.76 % 21.80 % 22 February, 2021 Franklin Templeton Investment Funds Franklin Biotechnology Discovery Fund A (acc) USD This fund is managed by Franklin Templeton International Services S.à r.l.
    [Show full text]
  • 2021 Jp Morgan Healthcare Conference
    Cover page, paste image over entire page 2021 J.P. MORGAN HEALTHCARE CONFERENCE: DAY 1 January 2021|1 Summary The 39th annual J.P. Morgan Healthcare Conference (JPM) is being held virtually from January 11-14, 2021. A list of events and catalysts that were announced or updated at the conference today is included in this report. Below are some key points from today’s company presentations. Key Takeaways - Day 1 Mega Cap Companies • Amgen (AMGN) Chairman and CEO, Robert Bradway, started his presentation by focusing on Amgen’s two late stage assets, sotorasib and tezepelumab, at the J.P. Morgan Healthcare Conference given their large impact events expected this year, their potential to be first-in-class therapies, and the large unmet need they would be addressing in their indications. Key data catalysts for sotorasib in 2021 include a release of full Phase II results in KRAS G12C- mutant advanced NSCLC patients on January 29th at the World Lung Conference, Phase II colorectal cancer data in the first half of 2021, and initial data on several combinations with the KRAS inhibitor also in the first half of 2021. Regulatory submissions for sotorasib have been completed in the US and EU, and management indicates they are accelerating global launch preparations for sotorasib in anticipation of projected approvals this year. Successful approval would provide an effective targeted therapy option for previously treated NSCLC patients who have KRAS G12C-mutated locally advanced or metastatic, which account for 13% of the NSCLC patient population. In the long term, the Company indicates a possible exploration of label expansions to earlier lines of therapy and/or combinations with other therapies.
    [Show full text]
  • FDA Sets Stage to Authorize Moderna's Covid-19 Vaccine
    P2JW351000-5-A00100-17FFFF5178F ***** WEDNESDAY,DECEMBER 16,2020~VOL. CCLXXVI NO.142 WSJ.com HHHH $4.00 DJIA 30199.31 À 337.76 1.1% NASDAQ 12595.06 À 1.2% STOXX 600 392.84 À 0.3% 10-YR. TREAS. g 9/32 , yield 0.921% OIL $47.62 À $0.63 GOLD $1,852.30 À $23.60 EURO $1.2155 YEN 103.66 Holiday Lockdown Looms in London as Cases Surge EU Seeks What’s News Tougher Oversight Business&Finance Of Tech uropean officials want Enewpowers to oversee in- ternal workingsatlarge tech Firms companies,backed by threats of multibillion-dollarfines,as they seek to expand their role Proposals aim to boost as global tech enforcers. A1 Twitterwas fined under social-media policing, the EU’scurrent privacylaw, levy huge fines for afirst foraU.S.tech firm in a cross-border case sincethe competitive abuses rules went into effect. B4 BY SAM SCHECHNER Mnuchin suggested he was unlikely to support a European officials want new consent order to end the gov- powers to oversee internal ernment conservatorships GES workingsatlarge technology of Fannie and Freddie be- IMA companies such as Facebook fore Trump leavesoffice. A2 Inc., backed by threatsofmulti- ETTY U.S. stocks rallied, with /G billion-dollar fines,asthey seek the S&P 500, Nasdaq and to expand their role as global Dow advancing 1.3%, 1.2% tech enforcers. and 1.1%, respectively. B12 SUMMERS TheEuropean Union’sexecu- tivearm proposed two bills on High-frequency traders PETER IN LIGHTS: LondoN taverns like the Churchill Arms prepared for new restrictions that will take effect Wednesday, limiting Tuesday—one focused on illegal are using an experimental restaurants and pubs to takeaway and delivery.
    [Show full text]
  • Schedule of Investments(A) March 31, 2021 (Unaudited)
    Schedule of Investments(a) March 31, 2021 (Unaudited) Shares Value Shares Value Common Stocks & Other Equity Interests–99.60% Electrical Components & Equipment–3.35% Aerospace & Defense–0.49% Hubbell, Inc. 21,713 $ 4,057,943 Curtiss-Wright Corp. 10,338 $ 1,226,087 Rockwell Automation, Inc. 16,189 4,297,208 8,355,151 Apparel Retail–1.42% Ross Stores, Inc. 29,468 3,533,508 Electronic Equipment & Instruments–2.15% (b) Keysight Technologies, Inc. 37,390 5,361,726 Apparel, Accessories & Luxury Goods–0.75% Tapestry, Inc. 45,472 1,873,901 Environmental & Facilities Services–1.72% Republic Services, Inc. 43,052 4,277,216 Application Software–6.18% (b) Aspen Technology, Inc. 9,886 1,426,846 Financial Exchanges & Data–2.43% Citrix Systems, Inc. 12,132 1,702,848 Intercontinental Exchange, Inc. 31,186 3,482,853 Manhattan Associates, Inc.(b) 32,246 3,785,035 Tradeweb Markets, Inc., Class A 34,622 2,562,028 Paylocity Holding Corp.(b) 13,296 2,391,020 6,044,881 Q2 Holdings, Inc.(b) 11,477 1,149,995 Synopsys, Inc.(b) 19,925 4,937,017 Food Distributors–1.43% Sysco Corp. 45,350 3,570,859 15,392,761 Gas Utilities–2.40% Asset Management & Custody Banks–1.02% Atmos Energy Corp. 37,397 3,696,693 Northern Trust Corp. 24,104 2,533,571 Southwest Gas Holdings, Inc. 33,060 2,271,553 Auto Parts & Equipment–1.06% 5,968,246 Visteon Corp.(b) 21,592 2,633,144 General Merchandise Stores–1.01% Automotive Retail–2.88% Dollar General Corp.
    [Show full text]
  • SEAGEN INC. (Exact Name of Registrant As Specified in Its Charter)
    Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-32405 SEAGEN INC. (Exact name of registrant as specified in its charter) Delaware 91-1874389 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 21823 30th Drive SE Bothell, Washington 98021 (Address of principal executive offices, including zip code) (Registrant’s telephone number, including area code): (425) 527-4000 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 SGEN The Nasdaq Stock Market LLC Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
    [Show full text]
  • Putnam Dynamic Asset Allocation Balanced Fund the Fund's Portfolio 12/31/20 (Unaudited)
    Putnam Dynamic Asset Allocation Balanced Fund The fund's portfolio 12/31/20 (Unaudited) COMMON STOCKS (63.8%)(a) Shares Value Basic materials (2.5%) Akzo Nobel NV (Netherlands) 15,491 $1,664,032 Albemarle Corp. 28,035 4,135,723 Anglo American PLC (United Kingdom) 105,267 3,506,160 AptarGroup, Inc. 9,500 1,300,455 Ashland Global Holdings, Inc. 10,600 839,520 Axalta Coating Systems, Ltd.(NON) 43,500 1,241,925 BHP Billiton, Ltd. (Australia) 91,530 2,981,947 BHP Group PLC (United Kingdom) 32,815 864,801 Brenntag AG (Germany) 20,774 1,607,677 Celanese Corp. 6,900 896,586 Chemours Co. (The) 27,100 671,809 Compagnie De Saint-Gobain (France)(NON) 65,695 3,012,317 Covestro AG (Germany) 22,344 1,378,238 CRH PLC (Ireland) 153,383 6,483,859 Dow, Inc. 79,622 4,419,021 DuPont de Nemours, Inc. 38,372 2,728,633 Eastman Chemical Co. 23,100 2,316,468 Eiffage SA (France)(NON) 6,566 634,694 Fortescue Metals Group, Ltd. (Australia) 67,947 1,228,505 Fortune Brands Home & Security, Inc. 27,161 2,328,241 Freeport-McMoRan, Inc. (Indonesia) 258,277 6,720,368 ICL Group, Ltd. (Israel) 70,941 362,082 Koninklijke DSM NV (Netherlands) 10,216 1,759,869 LafargeHolcim, Ltd. (Switzerland) 22,082 1,211,799 Linde PLC 4,131 1,072,836 NewMarket Corp. 1,100 438,119 Nitto Denko Corp. (Japan) 7,900 709,366 PPG Industries, Inc. 8,000 1,153,760 Reliance Steel & Aluminum Co.
    [Show full text]